September 25, 2014

Reading Between the (Guide)lines to Manage Pediatric UTI and Vesicoureteral Reflux

Tips for conundrums the guidelines don’t address

UTI_Primary_690x380

By Halima Janjua, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Diagnostic and treatment guidelines for urinary tract infection (UTI) issued by the American Academy of Pediatrics fall short of providing all the answers a pediatrician may need. The same goes for guidelines on primary vesicoureteral reflux (VUR) issued by the American Urological Association.

Both sets of guidelines fail to address frequent clinical challenges — or at least fail to do so with the specificity that real-world practice can demand. To fill this void, I and my colleagues in Cleveland Clinic Children’s Centers for Pediatric Nephrology and Urology generally rely on the principles outlined below to handle UTI and VUR challenges for which guideline recommendations are lacking .

I invite perspectives on these principles — and additional recommendations for addressing neglected challenges in UTI/VUR management — from colleagues across the nation.

Advertisement

Diagnosis

  • Persistent high fever is not a reliable differentiator between upper and lower UTI. The risk of renal scarring is comparable in children with and without persistent high fever. Therefore, we recommend meticulous treatment and prevention of both nonfebrile and febrile UTI.
  • Evaluation for VUR is required when children younger than 2 years of age have an abnormal renal ultrasound or more than one febrile UTI, as recommended by the American Academy of Pediatrics. We do not routinely perform voiding cystourethrography (VCUG) in children older than 2 who have symptoms of lower urinary tract dysfunction.
  • Assessment for renal scarring with a dimercaptosuccinic acid (DMSA) renal scan is also recommended when renal and bladder ultrasonography is abnormal, when there is grade III-V VUR, or in the presence of hypertension, proteinuria or elevated serum creatinine.

Antibiotic therapy

  • Initial uncomplicated cystitis should be treated with five to seven days of oral antibiotics.
  • Febrile UTI and complicated or recurrent cystitis merit 10 to 14 days of oral antibiotics.
  • Intravenous therapy is needed for infants younger than 1 month or for children who have high-grade fever for more than 48 hours after initiating antibiotics, who present with nausea and vomiting, or who require rehydration.
  • Broader antibiotic coverage for Enterococcus and/or Pseudomonas and a renal ultrasound are required when febrile UTI fails to defervesce in 48 hours despite adequate treatment.

Test of cure

  • Repeat urine cultures are not recommended to prove eradication of UTI except in cases of recurrent infections, infections with drug-resistant organisms, immunosuppression or urological abnormalities.

Antibiotic prophylaxis

  • Infants younger than 1 year with febrile UTI and any grade VUR, or with grade III-V VUR, require prophylaxis.
  • Children of any age with bladder/bowel dysfunction and VUR require prophylaxis due to increased risk of UTI while the bladder/bowel dysfunction is being treated. Symptoms include urinary incontinence, dysuria, urinary frequency or infrequent voiding, constipation and encopresis. Children with VUR and bladder/bowel dysfunction may be at increased risk for renal damage.
  • Bladder/bowel dysfunction tends to increase the risk of breakthrough UTI in children on antibiotic prophylaxis.

Bladder/bowel dysfunction: Beyond antibiotics

  • Treatments for bladder/bowel dysfunction may include constipation management, behavioral therapy, anticholinergic medications, alpha-blockers, biofeedback or pelvic floor muscle retraining.
  • Electromyography-based biofeedback therapy can be used to retrain pelvic muscles and strengthen and coordinate bladder contractions. Use of animated biofeedback encourages interest and helps attain results more quickly.

Dr. Janjua is a pediatric nephrologist in Cleveland Clinic Children’s Center for Pediatric Nephrology.

Related Articles

CQD-4408858-breastfeeding
December 19, 2023
A New Policy Update on Breastfeeding: What All Clinicians Need To Know

Cleveland Clinic physicians offer their insights

23-CHP-3988710 CQD Szugye – Breastfeeding Medicine Clinic
September 11, 2023
7 Clinical Takeaways for Providers Caring for Lactating Parents and Breastfeeding Infants

Increasing support for breastfeeding patients

22-CHP-3060258 CQD-Mudd-CARE Line-650×450
August 24, 2022
The CARE Line: What To Know About Cleveland Clinic Children’s Telephone Consultation Program

Program has facilitated nearly 300 consults across 25 departments in less than a year

22-CCC-2636467-CQD-Hero-650×450
January 21, 2022
No Level of Lead Is Safe in a Child’s Body

Though completely preventable, lead poisoning remains a public health threat

650×450-COVID-Sick-Child
March 18, 2021
Unique Aspects of COVID-19 in Children

Differences in infection rates, management, outcomes and transmission

650×450-Speech-Therapy
February 9, 2021
Ultrasound Technology Valuable in Remediating Common Articulation Disorder

Helps patients visualize proper tongue placement

Ad